Skip to main content
Show — Main navigation
Hide — Main navigation
Home
About
The Chair
Inquiry Team
Expert Groups
Inquiry Intermediaries
Core Participants
Legal Representatives
Financial Reports
Approach
Terms of reference
List of Issues
Statements of approach
Inquiry Principles
News
News
Newsletter Archive
Reports
The Inquiry Report
Additional Compensation Report
First Interim Report
Second Interim Report
Compensation Framework Study
Evidence
Evidence
Hearings Archive
Compensation
Support
NHS Psychological Support
Confidential Psychological Support
Support Groups
Infected Blood Support Schemes
Treatment and aftercare
Medical Evidence
Expenses Guidance
Contact us
Search
Accessibility Tool
Zoom in
Zoom out
Reset
Contrast
Accessibility tool
Listen
Get in touch
Quick Exit
Subscribe to Search results
Search
Sort your search results
Relevance
Title
Changed
At its first meeting, the UK Working Party on Transfusion-Associated Hepatitis agreed that Dr Gunson would ask the MRC if samples from the 1974 UK prospective study on transfusion associated hepatitis could be made available.
Published on:
24 July, 2024
Dr Gunson asked the MRC if samples from the 1974 UK prospective study on transfusion associated hepatitis could be made available.
Published on:
24 July, 2024
The MRC sought further information on Dr Gunson's request on samples from the 1974 UK prospective study on transfusion associated hepatitis, including where Dr Gunson believed the samples might be held.
Published on:
24 July, 2024
Dr Brian McClelland outlined two options for the 1974 UK prospective hepatitis study and suggested that a multi-centre study of this type would cost between £250,000 and £500,000.
Published on:
11 October, 2024
Dr Brian McClelland contacted Dr James regarding an abstract of prospective study on possible non-A non-B post-transfusion and the availability of samples from their study.
Published on:
24 July, 2024
Dr James expressed a willingness to collaborate with the Working Party on providing samples from their earlier study while noting he and his colleagues wished to avoid defrosting and refreezing their stored sera on too many occasions.
Published on:
24 July, 2024
Dr Gunson stated in a letter to Dr Keith Gibson that unless they were able to obtain data relating to the situation within the UK, they may be placed in the position of taking up a test, for medico-legal considerations if nothing else, developed abroad where the incidence or characteristics of the illness differs from that in the UK and such a decision could cost the NHS millions each year.
Published on:
24 July, 2024
Dr Gibson of the MRC informed Dr Gunson that many of the samples from the previous MRC study had been lost as a result of power failures, an audit of what was left would be carried.
Published on:
24 July, 2024
Professor Zuckerman informed Dr Gibson that a duplicate set of samples had been disposed of.
Published on:
24 July, 2024
Dr Gunson told the Working Party on Transfusion Associated Hepatitis that many of the samples from his previous MRC study had been lost due to a power failure. The Working Party acknowledged that this ruled out the chance of updating the testing of samples from that study with modern diagnostic assays.
Published on:
24 July, 2024
The Working Party on Transfusion Associated Hepatitis noted that no source of funding had been found to date for Dr Brian McClelland's proposed study.
Published on:
24 July, 2024
The Working Party on Transfusion Associated Hepatitis discussed the possibility of seeking funding from the MRC for a joint study involving Edinburgh and the North London Blood Transfusion Centre. Dr John Barbara planned to speak to the Director and submit a draft proposal.
Published on:
24 July, 2024
The Working Party on Transfusion Associated Hepatitis discussed potential requests to Dr James of the Freeman Hospital for access to samples from his prospective study of 248 patients who had undergone cardiac surgery.
Published on:
24 July, 2024
Dr James and his colleagues published the results of a study on post-transfusion hepatitis after cardiac surgery which suggested that NANBH after blood transfusion "from a largely British blood donor group probably leads to clinically significant chronic liver disease very rarely indeed."
Published on:
24 July, 2024
In oral evidence to the Inquiry, Dr Brian McClelland stated that he never saw a follow-up proposal from Dr Barbara in relation to a joint study involving Edinburgh and the North London Blood Transfusion Centre.
Published on:
24 July, 2024
In oral evidence to the Inquiry, Dr Brian McClelland described the transfusion service as "losing sight of" NANBH for several years from 1983 due to preoccupation with HIV/AIDS.
Published on:
24 July, 2024
In oral evidence to the Inquiry, Dr Brian McClelland explained that ALT levels was only a small element of his proposal for a comprehensive study.
Published on:
24 July, 2024
In oral evidence to the Inquiry, Dr Brian McClelland accepted that nothing had really moved on since the beginning of the 1980s in relation to NANBH surrogate screening study.
Published on:
24 July, 2024
In oral evidence to the Inquiry, Dr Brian McClelland explained that the letter "Testing blood donors for Non-A, Non-B Hepatitis: irrational, perhaps, but inescapable" published in the Lancet was written partly out of extreme frustration at the fact that the appropriate epidemiological studies with donors and recipients had repeatedly not been done.
Published on:
24 July, 2024
In oral evidence to the Inquiry, Dr Brian McClelland agreed with the description of "decision paralysis" in relation to the situation with introduction of surrogate screening and undertaking of the respective study from the early 1980s through to the end of 1988.
Published on:
09 October, 2024
Pagination
First page
First
Previous page
Previous
…
Page
2014
Page
2015
Page
2016
Page
2017
Current page
2018
Page
2019
Page
2020
Page
2021
Page
2022
…
Next page
Next
Last page
Last